Nov 5, 2020 11:50 am EST Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
Nov 2, 2020 9:00 am EST Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
Sep 9, 2020 8:00 am EDT Ocuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September
Jan 22, 2020 7:00 am EST Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
Nov 7, 2019 7:41 am EST Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol® Eye Drops
Sep 4, 2019 5:23 pm EDT Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops
Aug 7, 2019 6:30 am EDT Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development